8 citations,
December 2017 in “Cancer Medicine” Finasteride use may increase the risk of male breast cancer.
7 citations,
March 2019 in “Cancer Epidemiology, Biomarkers & Prevention” Finasteride use is not clearly linked to an increased risk of male breast cancer.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
4 citations,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
4 citations,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
4 citations,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
3 citations,
July 2018 in “Cureus” A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.
3 citations,
August 2013 in “Journal of the National Cancer Institute” The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.
2 citations,
March 2021 in “Cutis” Some breast cancer treatments, like taxanes, can cause long-term hair loss.
1 citations,
April 2016 in “Plastic and Reconstructive Surgery – Global Open” Oncoplastic breast surgery is more cost-effective than standard lumpectomy for large-breasted women despite being more expensive.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
September 2003 in “Journal of the Royal Society of Medicine” Understanding breast cancer requires considering both medical advancements and social influences.
67 citations,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
61 citations,
April 2009 in “British journal of dermatology/British journal of dermatology, Supplement” Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.
42 citations,
January 2005 in “Applied spectroscopy” Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.
23 citations,
October 2007 in “International journal of cancer” X-ray diffraction of hair might help detect breast cancer non-invasively.
22 citations,
January 1985 in “Annals of Internal Medicine” Minoxidil in breast milk may harm nursing infants.
17 citations,
May 2019 in “Journal of International Medical Research” Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.
15 citations,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
6 citations,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
5 citations,
June 2022 in “Frontiers in Endocrinology” Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.
5 citations,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
3 citations,
November 2022 in “Advances in Clinical and Experimental Medicine” Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.
2 citations,
December 2013 in “Cancer Research” Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.
2 citations,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
2 citations,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
1 citations,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
1 citations,
November 2019 in “Archives of breast cancer” Some hormone treatments might raise breast cancer risk, while others don't seem to.